Sirolimus by OrphAI Therapeutics for Bronchiolitis Obliterans: Likelihood of Approval

Sirolimus is under clinical development by OrphAI Therapeutics and currently in Phase II for Bronchiolitis Obliterans.

No Relief From Drug Shortages; New Lymphedema Guideline; A ‘Good’ Patient No More

Drug shortages persist, as the FDA faces multiple challenges in its oversight of COVID-19-related production disruptions at foreign manufacturing facilities. (BioSpace) A wrongful death lawsuit

February 10, 2024

Psychiatric Hospital Chain’s Charges; Schizophrenia Drug Flops; Bright Light Therapy

Acadia Healthcare, a nationwide chain of psychiatric hospitals, faces new federal charges after it just agreed to a nearly $20 million settlement over accusations it

October 3, 2024

Using Pap smears for earlier ovarian cancer detection shows promise in small new study

Ovarian cancer owes its often-dismal prognosis to the late stage at which it’s typically discovered. If a tumor is found when it’s small and cancer

December 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.